Development and application of a UHPLC-MS/MS method for the simultaneous determination of firmonertinib and its main metabolite AST-5902 in rat plasma: a study on the <i>in vivo</i> drug interaction between firmonertinib and paxlovid.

Front Pharmacol · 2025 · PMC12104055 · PMID 40421224

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

extremely significantno p-value reported

During the COVID-19 pandemic, not only do cancer patients have the risk of being infected with COVID-19 and suffering from severe adverse prognoses, but the delays in the diagnosis and treatment of cancer can also exert an extremely significant negative influence on the cancer progression of patients.

also in 7,787 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Development and application of a UHPLC-MS/MS method for the simultaneous determination of firmonertinib and its main metabolite AST-5902 in rat plasma: a study on the &lt;i&gt;in vivo&lt;/i&gt; drug interaction between firmonertinib and paxlovid.

The sentences

Development and application of a UHPLC-MS/MS method for the simultaneous determination of firmonertinib and its main metabolite AST-5902 in rat plasma: a study on the <i>in vivo</i> drug interaction between firmonertinib and paxlovid.